Plus Therapeutics to Showcase Breakthroughs in CNS Cancer Treatments at SNO/ASCO 2024 Conference

Plus Therapeutics,  a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, will have multiple opportunities to present data at the 2024 Society for Neuro-Oncology (SNO) / American Society for Clinical Oncology (ASCO) CNS Metastases Conference August 8-10, in Denver, Colorado.

“This year’s SNO/ASCO Metastases conference is a key opportunity for Plus to highlight advancements in our LM therapeutics and diagnostics programs,” said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. “The conference gathers key influencers and clinicians to discuss important topics in the field and we are honored to have multiple opportunities to share our results with the scientific community.”

 

Events and data presentations include:

Symposium:

The Company will be hosting a symposium titled, “Emerging Novel Diagnostic and Therapeutic Approaches for Leptomeningeal Metastases” on August 8, 2024, at 6:15-7:15 p.m. MDT in the Plaza Ballroom (DEF) of the Sheraton Denver Downtown Hotel. Speakers include:

• Greg Fuller, M.D., Ph.D., Plus Therapeutics Medical Director and VP of Medical Affairs; Former Chief, Section of Neuropathology, The University of Texas MD Anderson Cancer Center
• Seema Nagpal, M.D., Clinical Professor, Neurology & Neurological Sciences, Stanford University
• Jonathan Yang, M.D., Ph.D., Associate Vice Chair for Clinical Research and Developmental Therapeutics, Department of Radiation Oncology, Director of Clinical Research, NYU Langone Health’s Perlmutter Cancer Center
• Andrew Brenner, M.D., Ph.D., Professor and Kolitz / Zachry Endowed Chair Neuro-Oncology Research; Co-Leader, Experimental and Developmental Therapeutics Program, University of Texas Health, Science Center at San Antonio

 

Therapeutic:

Title: Phase 1 Dose Escalation of Rhenium (186Re) Obisbemeda (Rhenium Nanoliposome,186RNL) for the Treatment of Leptomeningeal Metastases (LM): Ongoing Clinical Study Update for Initial Safety and Feasibility), OCTS-11

Presenter: Andrew Brenner, M.D., Ph.D.

Date/Time: Friday, 09 August 2024, 1:10-2:30 p.m. MDT

Location: Plaza Ballroom (ABC)

 

Title: Radiation Absorbed Dose to Spinal Cord: Therapy of Leptomeningeal Metastases Using Beta-Emission Radiopharmaceuticals, RMTD-08

Presenter: Ande Bao, Ph.D., M.S., Assistant Professor, Department of Radiation Oncology, School of Medicine at Case Western University

Date/Time: Thursday, 08 August 2024, 7:15-09:00 p.m. MDT

Location: Plaza Exhibit Hall

 

Diagnostic:

Title: CSF Tumor Cell (CSF-TC) Detection, Quantification and Biomarker assessment helps in clinical management of breast cancer and Non-Small Cell Lung cancer patients having Leptomeningeal Disease (FORESEE Study, NCT05414123), BMRK-13

Presenter: Priya Kumthekar, M.D., Associate Professor of Neurology and Hematology/Oncology, Northwestern University Medical School

Date/Time: Saturday, 10 August 2024, 08:45-10:05 a.m. MDT

Location: Plaza Ballroom (ABC)

 

Title: The CNSide CSF Tumor Cell detection platform is a feasible, clinically relevant and scalable platform for disease management for patients with Leptomeningeal Disease, BMRK

Presenter: Arushi Tripathy, M.D., Neurosurgery PGY-4 Resident at University of Michigan Medical School

Date/Time: Thursday, 08 August 2024, 7:15-9:00 p.m. MDT

Location: Plaza Exhibit Hall

 

About Leptomeningeal Metastases (LM)

LM is a rare complication of cancer in which the primary cancer spreads to the cerebrospinal fluid (CSF) and leptomeninges surrounding the brain and spinal cord. All malignancies originating from solid tumors, primary brain tumors, or hematological malignancies have this LM complication potential with breast cancer as the most common cancer linked to LM, with 3-5% of breast cancer patients developing LM. Additionally, lung cancer, GI cancers and melanoma can also spread to the CSF and result in LM. LM occurs in approximately 5% of people with cancer and is usually terminal with 1-year and 2-year survival of just 7% and 3%, respectively. The incidence of LM is on the rise, partly because cancer patients are living longer and partly because many standard chemotherapies cannot reach sufficient concentrations in the spinal fluid to kill the tumor cells, yet there are no FDA-approved therapies specifically for LM patients, who often succumb to this complication within weeks to several months, if untreated.